Roche: Oddo BHF maintains neutral rating after Q3 results
(CercleFinance.com) - Despite a new "good quarter" for Roche, Oddo BHF said today that it is maintaining its neutral rating on the Roche stock, expecting 2019 to be a year that “promises to be difficult”.
In 2019 Roche will be confronted with the arrival of biosimilars in the US and this will have an impact on top-line growth, as well as the group's margins, Oddo BHF said.
The broker is also maintaining its target price of 267 Swiss francs for the share.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
In 2019 Roche will be confronted with the arrival of biosimilars in the US and this will have an impact on top-line growth, as well as the group's margins, Oddo BHF said.
The broker is also maintaining its target price of 267 Swiss francs for the share.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.